TaiGen Biopharmaceuticals (太景-KY) announced on December 11 that its partner, Joincare Pharmaceutical Group, has received official notice from the National Medical Products Administration (NMPA) granting an Innovative Drug Marketing Authorization (NDA approval) for Pixavir marboxil (TG-1000) oral capsules. Positioned as a "blockbuster drug," Pixavir will target the high-end influenza market in China, estimated at RMB 10 billion.

Clinical and Strategic Highlights:

• Mechanism of Action: Pixavir is a self-developed innovative drug that precisely blocks the "cap-snatching" mechanism required for influenza virus replication. Unlike traditional treatments requiring a five-day, twice-daily regimen, Pixavir’s core advantage is its single-dose oral regimen, significantly improving patient compliance for adolescents and active adults.
• Clinical Efficacy: Phase 3 data confirmed superior safety and efficacy against both Influenza A and B. Symptom relief was shortened by 27 hours compared to placebo ($P < 0.0001$), and fever reduction was accelerated by 24.6 hours. Notably, for the difficult-to-treat Influenza B, symptom relief was significantly shortened by 31 hours ($P < 0.05$).
• Market Entry Strategy: Joincare has branded the drug "Yi-Li-Kang" (壹立康) to emphasize rapid recovery after a single dose. Initial commercial efforts will focus on the out-of-pocket (self-pay) retail market through academic promotion, large pharmacy chains, and online platforms before seeking inclusion in the National Reimbursement Drug List (NRDL).

Resource: 太景Pixavir流感新藥在大陸核准上市 將搶攻人民幣百億元市場商機